G1GLP1 Note Applies to All countries

HomeGenericsZepbound

GenericAll countries · Checked

Tirzepatide Generic Name: Is Generic Tirzepatide Available?

Tirzepatide is the generic name of Mounjaro and Zepbound. As of November 20, 2026, the US has approved no generic tirzepatide, and four generic applications are waiting for FDA review.

Is there a generic tirzepatide?

Not yet. No generic is approved, and the brand medicines are the only approved products.

Generic nameTirzepatide

Brand namesZepbound, Mounjaro

US generic applications4 accepted for review, 0 approved

The maker is Eli Lilly. Based on the US prescribing information and the generic makers' announcements.

With no generic, you pay the brand price today.

See the price of each Zepbound dose in the US

Paying out of pocket? See Zepbound savings card and LillyDirect prices.

Generic nameApproved?WhenZepboundMounjaroFormsDoseMeanwhileOther drugsApproval datesFAQ

Tirzepatide generic name

Tirzepatide is the name of the active ingredient. Mounjaro and Zepbound are brand names for it.

Both brands contain the same medicine, and the two names exist because the US approvals differ.

Zepbound is approved to reduce and maintain body weight and to treat moderate to severe sleep apnea in adults with obesity. Mounjaro is approved for type 2 diabetes.

Tirzepatide acts on two receptors, GIP and GLP-1, and is injected under the skin once a week.

Generic tirzepatide: what is approved

In the US, the number of approved generic tirzepatide products is zero.

Four applications exist, and the FDA has accepted them for review. Accepted for review does not mean approved.

US generic tirzepatide applications

Sandoz, announced June 29, 20262 accepted, autoinjector

Adalvo and Amneal, announced July 1, 20262 accepted, one per brand

Approved generics0

The Adalvo and Amneal applications seek approval for all approved autoinjector presentations and uses of both brands, which include type 2 diabetes and chronic weight management.

When will generic tirzepatide be available?

No date is set. A generic can launch only after the FDA approves it.

For the Sandoz applications, the FDA has not confirmed a final review timeline.

Adalvo and Amneal say the products are in development subject to FDA approval, and neither company gives an approval or launch date. Amneal would lead commercialization.

Until then, people who take tirzepatide use the brand medicines at brand prices.

Generic Zepbound

A generic version of Zepbound would be sold under the name tirzepatide, not under a new brand.

One Adalvo and Amneal application references Zepbound, and the two Sandoz applications reference both brands.

The medicine itself is in Zepbound (tirzepatide), and the doses are in Zepbound dosing schedule.

Generic Mounjaro

Generic Mounjaro would be the same tirzepatide, and the situation is the same: no approved product, applications under review.

The Mounjaro angle has its own page in Mounjaro generic name.

Prices outside the US are in Mounjaro price UK, India, Australia and Canada.

Zepbound forms a generic would copy

Zepbound comes as a single-dose pen and a single-dose vial, each in 2.5, 5, 7.5, 10, 12.5 and 15 mg.

There are also a multi-dose vial and a KwikPen, with four doses in each.

The pending applications are for autoinjector products. Vials are not part of what the companies describe.

A generic is approved as the same as the brand: the same ingredient, the same strength and the same way of giving it.

Tirzepatide dose, and will a generic match it?

With no approved generic, there is nothing to compare yet.

Zepbound starts at 2.5 mg once a week for 4 weeks, then rises in 2.5 mg steps after at least 4 weeks.

The weight management maintenance doses are 5 mg, 10 mg or 15 mg, and 15 mg once a week is the maximum.

Your prescriber sets your dose. Even after a generic exists, do not switch products or change your dose on your own.

The full chart is in the dose schedule tool and in Mounjaro dosing.

What to do while there is no generic

If you already take tirzepatide, keep taking it as prescribed. Waiting for a generic is not a reason to skip a weekly dose.

A missed dose can be taken within 4 days (96 hours). After that, skip it. The details and the half-life of about 5 days are in tirzepatide half-life.

Where and how to inject is in Mounjaro injection sites. Whatever product you use, follow the instructions that come with your pen.

If cost is the worry, start with Zepbound cost in the US and Mounjaro savings card rules.

Do not use Zepbound with other tirzepatide products or with any GLP-1 medicine. The US label does not recommend it.

Generic versions of other weight loss drugs

Unlike tirzepatide, liraglutide already has generic versions in some countries, including the UK, Brazil and India.

Semaglutide has generic versions in Canada, India and Brazil, with approvals and launches in 2026.

Each drug has its own page: generic semaglutide, generic liraglutide, Wegovy generic name and generic Ozempic.

The wider picture is in generic GLP-1 drugs.

Tirzepatide approval dates

The FDA approved Zepbound for chronic weight management on November 8, 2023.

This page is updated when the FDA approves a generic or when an application changes status. Other approval dates are in tirzepatide FDA approval.

Tirzepatide generic FAQ

What is the generic name of Mounjaro and Zepbound?

Tirzepatide. Both brands contain it.

Can I buy generic tirzepatide?

No. No generic is approved, so the brands are the only approved products.

Will the price drop when a generic arrives?

Nobody can say yet. A generic price is set only when a product is approved and launched.

Are Zepbound and Mounjaro the same medicine?

Yes. Both are tirzepatide. In the US they carry different names because they are approved for different uses.

How long does the FDA take to decide on a generic application?

No date is fixed. The FDA has not confirmed a final timeline for the Sandoz applications.

Keep reading

Zepbound cost 2026: price per dose

Zepbound dosing chart

Mounjaro generic name

Generic semaglutide

Tirzepatide half-life

Tirzepatide FDA approval

This page follows the official prescribing information and company announcements, and it is updated when the status changes. See how we check our pages.

Update log

: First published.

Sources

Zepbound US prescribing information (Eli Lilly).

Mounjaro US prescribing information (Eli Lilly).

Adalvo and Amneal announce FDA acceptance of generic tirzepatide applications, July 1, 2026.

FDA accepts Sandoz applications for generic tirzepatide (Drug Topics, July 3, 2026, reporting the Sandoz announcement of June 29, 2026).

GLP1 Note is an independent information site. Your own treatment is decided by your prescriber.